INDIAGLYCO Latest Share Price (INDIAGLYCO)
TODAY IN ONE LINE
With a market cap of ₹1,981.98 Cr., it trades at a P/E of 6.47. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
INDIAGLYCO flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 31.9% YoY
- ●High Promoter HoldingPromoters hold 59.6% skin-in-the-game
- ●Steady Dividend YieldReliable 4.23% dividend yield
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest INDIAGLYCO News
What changed recently?
Recent events, corporate actions, and announcements.
INDIAGLYCO valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for INDIAGLYCO, framed against the sector median so the premium or discount is obvious at a glance.
INDIAGLYCO trades at a P/E of 6.47× and P/B of 0.71×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
INDIAGLYCO technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for INDIAGLYCO — derived from the latest tape, not yesterday's close.
INDIAGLYCO last traded at ₹1,111.7 with an intraday range of ₹1,097.5–₹1,173.7 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1111.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1310.17 | +198.47 | +17.85% |
| R3 | 1233.97 | +122.27 | +11.00% |
| R2 | 1203.83 | +92.13 | +8.29% |
| R1 | 1157.77 | +46.07 | +4.14% |
| PIVOT | 1127.63 | 15.93 | 1.43% |
| CURRENT | 1111.70 | — | — |
| S1 | 1081.57 | -30.13 | -2.71% |
| S2 | 1051.43 | -60.27 | -5.42% |
| S3 | 1005.37 | -106.33 | -9.56% |
| S4 | 929.17 | -182.53 | -16.42% |
INDIAGLYCO is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Below opening range, showing Bearishness
INDIAGLYCO financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for INDIAGLYCO — consolidated or standalone — with margins, YoY growth and key ratios inline.
INDIAGLYCO reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,981.98 Cr. and reported EPS of ₹14.45.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 9,039 | 9,827 ▲ 8.7% |
| Sales Growth YoY %Derived | 14.11% | 8.71% |
| Other Income | 15 | 5 ▼ 66.1% |
| Total Income | 9,054 | 9,832 ▲ 8.6% |
| 2,408 | 2,662 ▲ 10.6% | |
| Gross ProfitDerived | 6,631 | 7,165 ▲ 8.0% |
| Gross Margin %Derived | 73.36% | 72.91% |
| 6,120 | 6,515 ▲ 6.5% | |
| EBITDA (Operating Profit)Derived | 511 | 649 ▲ 27.1% |
| OPM %Derived | 5.65% | 6.61% |
| 280 | 322 ▲ 15.1% | |
| Profit Before Tax (PBT) | 246 | 331 ▲ 34.5% |
| 61 | 84 ▲ 37.5% | |
| Effective Tax %Derived | 24.97% | 25.53% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 231 | 293 ▲ 26.8% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | 231 | 293 ▲ 26.8% |
| Net Profit Margin %Derived | 2.55% | 2.98% |
| PAT Growth YoY %Derived | 33.49% | 26.78% |
| Earnings Per Share (EPS ₹) | 37.29 | 43.68 ▲ 17.1% |
| Diluted Shares Outstanding (Cr) | 6 | 7 ▲ 8.2% |
| Share of Profit from Associates/JVs | 46 | 46 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | -2 ▼ 24.6% |
| Total Expenses (incl. D&A & Interest) | 8,808 | 9,501 ▲ 7.9% |
| Material Cost % of RevenueDerived | 25.95% | 24.55% |
| Employee Cost % of RevenueDerived | 1.36% | 1.35% |
| Other Cost % of RevenueDerived | 66.35% | 64.95% |
| Interest Coverage (x)Derived | 2.41x | 2.95x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 4,162 | 5,117 ▲ 23.0% | 5,973 ▲ 16.7% | 5,427 ▼ 9.1% | 6,601 ▲ 21.6% | 6,642 ▲ 0.6% | 7,922 ▲ 19.3% | 9,039 ▲ 14.1% | 9,827 ▲ 8.7% | |
| Sales Growth YoY %Derived | — | 22.96% | 16.71% | -9.13% | 21.63% | 0.61% | 19.27% | 14.11% | 8.71% | |
| Other Income | 23 | 17 ▼ 26.9% | 9 ▼ 48.1% | 15 ▲ 74.0% | 22 ▲ 41.2% | 24 ▲ 10.9% | 26 ▲ 7.7% | 15 ▼ 43.5% | 5 ▼ 66.1% | |
| Total Income | 4,185 | 5,134 ▲ 22.7% | 5,981 ▲ 16.5% | 5,443 ▼ 9.0% | 6,623 ▲ 21.7% | 6,666 ▲ 0.6% | 7,947 ▲ 19.2% | 9,054 ▲ 13.9% | 9,832 ▲ 8.6% | |
2,003 | 2,073 ▲ 3.5% | 2,328 ▲ 12.3% | 1,499 ▼ 35.6% | 1,921 ▲ 28.2% | 1,582 ▼ 17.6% | 2,149 ▲ 35.8% | 2,408 ▲ 12.1% | 2,662 ▲ 10.6% | ||
| Gross ProfitDerived | 2,159 | 3,045 ▲ 41.1% | 3,644 ▲ 19.7% | 3,928 ▲ 7.8% | 4,680 ▲ 19.1% | 5,059 ▲ 8.1% | 5,773 ▲ 14.1% | 6,631 ▲ 14.9% | 7,165 ▲ 8.0% | |
| Gross Margin %Derived | 51.87% | 59.50% | 61.02% | 72.38% | 70.89% | 76.18% | 72.87% | 73.36% | 72.91% | |
1,835 | 2,628 ▲ 43.2% | 3,253 ▲ 23.8% | 3,660 ▲ 12.5% | 4,425 ▲ 20.9% | 4,764 ▲ 7.7% | 5,370 ▲ 12.7% | 6,120 ▲ 14.0% | 6,515 ▲ 6.5% | ||
| EBITDA (Operating Profit)Derived | 324 | 417 ▲ 28.9% | 392 ▼ 6.0% | 268 ▼ 31.6% | 255 ▼ 4.8% | 296 ▲ 15.8% | 402 ▲ 36.1% | 511 ▲ 27.0% | 649 ▲ 27.1% | |
| OPM %Derived | 7.77% | 8.15% | 6.56% | 4.94% | 3.87% | 4.45% | 5.08% | 5.65% | 6.61% | |
198 | 220 ▲ 10.8% | 226 ▲ 3.0% | 164 ▼ 27.8% | 371 ▲ 127.1% | 222 ▼ 40.2% | 221 ▼ 0.3% | 280 ▲ 26.3% | 322 ▲ 15.1% | ||
| Profit Before Tax (PBT) | 148 | 214 ▲ 44.2% | 174 ▼ 18.6% | 120 ▼ 31.3% | 348 ▲ 190.7% | 154 ▼ 55.9% | 207 ▲ 34.5% | 246 ▲ 19.0% | 331 ▲ 34.5% | |
51 | 81 ▲ 59.0% | 59 ▼ 26.4% | 11 ▼ 81.0% | 39 ▲ 249.6% | 24 ▼ 39.2% | 50 ▲ 110.0% | 61 ▲ 22.0% | 84 ▲ 37.5% | ||
| Effective Tax %Derived | 34.11% | 37.61% | 33.99% | 9.42% | 11.33% | 15.60% | 24.35% | 24.97% | 25.53% | |
| Profit/Loss from Discontinued Ops | — | — | — | 22 | 10 ▼ 54.2% | — ▼ 100.0% | — | — | — | |
| Total Profit for Period | 97 | 133 ▲ 37.4% | 115 ▼ 13.5% | 132 ▲ 14.8% | 340 ▲ 158.2% | 141 ▼ 58.5% | 173 ▲ 22.7% | 231 ▲ 33.5% | 293 ▲ 26.8% | |
| Less: Non-controlling Interests | — | — | — | — | — | 16 | — ▼ 100.0% | — | — | |
| Net Profit (Owner's PAT)Derived | 97 | 133 ▲ 37.4% | 115 ▼ 13.5% | 132 ▲ 14.8% | 340 ▲ 158.2% | 125 ▼ 63.2% | 173 ▲ 38.3% | 231 ▲ 33.5% | 293 ▲ 26.8% | |
| Net Profit Margin %Derived | 2.32% | 2.59% | 1.92% | 2.42% | 5.15% | 1.88% | 2.18% | 2.55% | 2.98% | |
| PAT Growth YoY %Derived | — | 37.38% | -13.54% | 14.78% | 158.23% | -63.20% | 38.30% | 33.49% | 26.78% | |
| Earnings Per Share (EPS ₹) | 15.59 | 21.38 ▲ 37.1% | 18.52 ▼ 13.4% | 21.25 ▲ 14.7% | 54.88 ▲ 158.3% | 20.20 ▼ 63.2% | 27.94 ▲ 38.3% | 37.29 ▲ 33.5% | 43.68 ▲ 17.1% | |
| Diluted Shares Outstanding (Cr) | 6 | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | 7 ▲ 8.2% | |
| Share of Profit from Associates/JVs | -1 | -1 ▲ 23.2% | -0 ▲ 57.3% | 1 ▲ 275.6% | 21 ▲ 2800.0% | 11 ▼ 45.5% | 17 ▲ 46.5% | 46 ▲ 178.5% | 46 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -0 ▼ 2100.0% | -1 ▼ 580.0% | 3 ▲ 324.3% | -0 ▼ 115.4% | 0 ▲ 185.1% | -0 ▼ 147.5% | -1 ▼ 584.2% | -2 ▼ 24.6% | |
| Total Expenses (incl. D&A & Interest) | 4,037 | 4,920 ▲ 21.9% | 5,807 ▲ 18.0% | 5,323 ▼ 8.3% | 6,275 ▲ 17.9% | 6,512 ▲ 3.8% | 7,741 ▲ 18.9% | 8,808 ▲ 13.8% | 9,501 ▲ 7.9% | |
| Material Cost % of RevenueDerived | 34.43% | 30.29% | 28.22% | 21.84% | 25.25% | 21.75% | 22.96% | 25.95% | 24.55% | |
| Employee Cost % of RevenueDerived | 2.33% | 1.97% | 1.92% | 1.54% | 1.35% | 1.34% | 1.30% | 1.36% | 1.35% | |
| Other Cost % of RevenueDerived | 41.76% | 49.38% | 52.54% | 65.90% | 65.68% | 70.39% | 66.49% | 66.35% | 64.95% | |
| Interest Coverage (x)Derived | 2.00x | 2.37x | 2.15x | 2.25x | 2.51x | 2.02x | 2.50x | 2.41x | 2.95x |
INDIAGLYCO segment analysis : revenue and profit mix.
Disclosed business segments at INDIAGLYCO with their share of revenue and profit, switchable between consolidated and standalone reporting.
INDIAGLYCO discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for INDIAGLYCO.
Our AI distills the core fundamental drivers supporting INDIAGLYCO, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
INDIAGLYCO's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding 59.63% signals management confidence and long-term commitment
Latest quarterly EPS grew 35.7% YoY; TTM EPS growth 31.9% reflects robust earnings momentum
Operating margin 11.73% demonstrates solid pricing power and cost control capabilities
Debt-to-equity 0.62x maintains moderate leverage, supporting strategic financial flexibility
Diversified portfolio across chemicals, spirits, and biopharma reduces sector concentration risk
Key Risks.
Latest quarterly EPS declined 20.9% sequentially despite YoY growth strength
Negative free cash flow in FY2025 and FY2024 raises liquidity and capital allocation concerns
Beta 1.39 indicates higher volatility than market, amplifying downside risk exposure
ROE 11.13% and ROCE 10.62% lag peer benchmarks, signaling capital inefficiency
Limited institutional ownership 3.52% reduces external oversight and market credibility
Flip Conditions.
Valuation risk. a P/E above 8 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.12. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
INDIAGLYCO peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — INDIAGLYCO is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
INDIAGLYCO chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for INDIAGLYCO — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
INDIAGLYCO delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for INDIAGLYCO over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in INDIAGLYCO stood at 66.8% of traded volume, against a 20-day average of 49.3%.
INDIAGLYCO announcements: results, concalls, ratings, M&A.
Filings INDIAGLYCO sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
INDIAGLYCO files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 183 documents below.
Updates
India Glycols Limited has informed the Exchange regarding 'Material Update in Connection with Ennature Bio Pharma Limited'.
Updates
India Glycols Limited has informed the Exchange regarding 'Material Update in Connection with IGL Spirits Limited'.
Updates
India Glycols Limited has informed the Exchange regarding 'Intimation of Schedule of Analyst / Institutional Investor Meeting.'.
Updates
India Glycols Limited has informed the Exchange regarding 'Material Update in Connection with Ennature Bio Pharma Limited with reference to…
Updates
India Glycols Limited has informed the Exchange regarding 'Material Update in Connection with IGL Spirits Limited with reference to Observation…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
INDIAGLYCO dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue INDIAGLYCO has declared, sequenced by announce and record date.
INDIAGLYCO corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About INDIAGLYCO: business, sector, key facts.
What INDIAGLYCO does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
INDIAGLYCO operates in the Breweries & Distilleries industry under the Fast Moving Consumer Goods sector, listed as NSE: INDIAGLYCO, BSE: 500201.
India Glycols Limited (IGL) is an Indian green petrochemical company primarily involved in the manufacturing and sale of a diverse range of industrial chemicals. Their business operations are segmented into three key areas: Bio-based Specialities and Performance Chemicals, Potable Spirits, and Ennature Biopharma. This diversified approach allows them to cater to a wide array of industrial and consumer needs.
The Bio-based Specialities and Performance Chemicals segment forms a significant portion of IGL's business. Here, they produce and market a broad spectrum of products, including various glycols (mono, di, and tri ethylene glycols), glycol ethers and acetates used in brake fluids, bio-polymers derived from guar and natural gums, and a selection of specialty chemicals. These specialty chemicals encompass a wide range of applications, from plasticisers and oil field chemicals to bio-amines, methyl soyate, MDEA and its derivatives, bio-potash granules, and their proprietary C-Smart specialty products. This segment highlights IGL's commitment to sustainable and bio-based alternatives within the chemical industry.
IGL's Potable Spirits segment focuses on the production and distribution of alcoholic beverages. Their brand portfolio includes a variety of whiskeys (Soulmate Blu and Single Reserve), vodka (Amazing), rum (Zumba and Beach House XXX), and economy spirits (Bunty), along with branded country liquor. This segment demonstrates IGL's expansion into the consumer goods market, leveraging their production capabilities to offer a selection of alcoholic drinks.
Finally, the Ennature Biopharma segment caters to the pharmaceutical and healthcare sectors. IGL produces natural active pharmaceutical ingredients (APIs), nutraceuticals, standardized botanical extracts, and nicotine derivatives. This segment underscores IGL's commitment to providing high-quality ingredients for the healthcare industry, complementing their offerings in other sectors.
In summary, India Glycols Limited operates across multiple sectors, showcasing a diversified business model. Their products find application in a vast array of industries including pharmaceuticals, textiles, automotive, personal care, industrial manufacturing, paints and coatings, oil and gas, food ingredients, packaging, and the spirits industry. Furthermore, IGL actively participates in the export market, distributing their products internationally.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- ALLIED BLEND N DISTILS L (ABDL) Share PricePeer
- ASSO ALCOHOLS & BREW (ASALCBR) Share PricePeer
- BCL INDUSTRIES (BCLIND) Share PricePeer
- GLOBUS SPIRITS (GLOBUSSPR) Share PricePeer
- G M BREWERIES (GMBREW) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about INDIAGLYCO (INDIAGLYCO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of INDIAGLYCO (INDIAGLYCO)?
The current share price of INDIAGLYCO (INDIAGLYCO) is ₹1,111.70. Today, the stock has declined by ₹35.60 (3.1%), trading in a range of ₹1,097.50 to ₹1,173.70. The stock opened at ₹1,149.80 with a trading volume of 8,80,527 shares.
02Is INDIAGLYCO stock a good investment for long-term?
INDIAGLYCO can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,981.98 Cr., P/E ratio of 6.47, ROE of 11.13%, and ROCE of 10.62%. The dividend yield stands at 4.23%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of INDIAGLYCO stock?
The 52-week high price of INDIAGLYCO (INDIAGLYCO) is ₹1,222.00, while the 52-week low is ₹792.50. Currently trading at ₹1,111.70, the stock is 40.28% above its 52-week low and 9.03% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy INDIAGLYCO stock at the current price?
Whether to buy INDIAGLYCO stock at ₹1,111.70 depends on multiple factors. The stock is currently trading with a P/E ratio of 6.47 and P/B ratio of 0.71. Today's performance shows a loss of 3.1%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of INDIAGLYCO and when is the next dividend?
INDIAGLYCO offers a dividend yield of 4.23%, which means for every ₹100 invested at the current price of ₹1,111.70, you can expect to receive approximately ₹4.23 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of INDIAGLYCO?
INDIAGLYCO's key financial metrics include: P/E Ratio: 6.47, P/B Ratio: 0.71, ROE: 11.13%, ROCE: 10.62%, Dividend Yield: 4.23%, EPS: ₹14.45, Book Value: ₹437.55, and Debt-to-Equity: 0.62. The company's market cap stands at ₹1,981.98 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is INDIAGLYCO stock performing today in the market?
INDIAGLYCO stock opened at ₹1,149.80 and is currently trading at ₹1,111.70, showing a decline of ₹35.60 (3.1%). The intraday high is ₹1,173.70 and low is ₹1,097.50. The trading volume stands at 8,80,527 shares, indicating moderate market participation today.
08What is the P/E ratio of INDIAGLYCO and what does it indicate?
INDIAGLYCO has a Price-to-Earnings (P/E) ratio of 6.47, which means investors are willing to pay 6.47 for every ₹1 of earnings. With an EPS of ₹14.45, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about INDIAGLYCO (INDIAGLYCO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.